Thursday, July 3, 2025 7/3/2025

Discovery and anti-tumor activity of the first antagonists targeting human Sonic Hedgehog autoprocessing

Award Number: R21CA282857
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/06/2024
PERIOD OF PERFORMANCE END DATE: 02/28/2026

Group Awards By:

View Award Description

Discovery and anti-tumor activity of the first antagonists targeting human Sonic Hedgehog autoprocessing - ABSTRACT We are pursuing the first anti-tumor small molecules that act specifically against human Sonic Hh protein autoprocessing, a unique biosynthetic event that is necessary to drive oncogenic hedgehog (Hh) ligand dependent cell/cell signaling. Sonic Hh protein autoprocessing involves a precursor form of Hh and is responsible for liberating the mature Sonic Hh signaling ligand while also modifying the ligand’s terminal carboxyl group with cholesterol. The long-standing challenge has been to discover small molecules that specifically antagonize this key reaction within the tumor cell. To facilitate discovery, we have devised the first in-cell assay system to screen for antagonists of human Hh autoprocessing at high throughput. Our assay couples intracellular Sonic Hh autoprocessing to the extracellular secretion of a bioluminescent reporter enzyme. We recently miniaturized this assay for 1536-well plates and in preliminary work, completed a successful pilot screen against LOPAC. Here we propose a two-year high risk/gain strategy that integrates: (AIM 1) In-cell quantitative high throughput screening in collaboration with the National Center for Advancing Translational Science (NCATS) to discover the first bioactive drug-like antagonists of human Sonic Hh autoprocessing; (AIM 2) Pre-clinical evaluation of the anti-tumor effects of those novel Hh autoprocessing inhibitors toward human multiple myeloma and human colon cancer cells, which exhibit Hh-ligand dependent growth. We hypothesize that specific antagonists of Sonic Hh autoprocessing will deplete extracellular Sonic Hh ligand. Tumor apoptosis is the expected result of this ligand deprivation strategy. In summary, using an innovative assay and novel anti-Hh approach, we are poised to address a significant gap in the field of Hh signaling while pursuing a new class of cancer therapeutics.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $219,881 )
2025	2025	THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK	4400 VESTAL PKWY E	BINGHAMTON	NY	13902	BROOME	USA	Cancer Treatment Research	000	2	2/13/2025	NON-COMPETING CONTINUATION	$197,893
2025	2025	THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK	4400 VESTAL PKWY E	BINGHAMTON	NY	13902	BROOME	USA	Cancer Treatment Research	001	2	5/22/2025	NON-COMPETING CONTINUATION	$21,988
														Subtotal = $219,881

Issue Date FY: 2024 ( Subtotal = $182,116 )
2024	2024	RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, THE	4400 VESTAL PKWY E	BINGHAMTON	NY	13902	BROOME	USA	Cancer Treatment Research	000	1	3/6/2024	NEW	$182,116
														Subtotal = $182,116

Grand Total All Awards = $401,997

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Discovery and anti-tumor activity of the first antagonists targeting human Sonic Hedgehog autoprocessing

Award Number: R21CA282857

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/06/2024

PERIOD OF PERFORMANCE END DATE: 02/28/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer